-+ 0.00%
-+ 0.00%
-+ 0.00%

Barinthus Biotherapeutics FY 2024 GAAP EPS $(1.55) Beats $(1.67) Estimate, Sales $14.97M Inline

Benzinga·03/20/2025 11:27:22
Listen to the news
Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(1.55) per share which beat the analyst consensus estimate of $(1.67) by 7.19 percent. This is a 18.85 percent increase over losses of $(1.91) per share from the same period last year. The company reported quarterly sales of $14.97 million which met the analyst consensus estimate. This is a 1.77K percent increase over sales of $802.00 thousand the same period last year.